Novel Insights into the Treatment of HCC and Liver Tumors

133.4K

views

359

authors

41

articles

Editors

5

Alessandro Vitale

University Hospital of Padua

University Hospital of Padua

Campus Bio-Medico University

Gabriele Spoletini

General Surgery and Liver Transplantation, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Francesco Giovinazzo

Department of Surgery, Saint Camillo Hospital

Impact

Fetching...

About

Tumors of the liver are one of the most common cancer types worldwide. Over recent decades the rate of incidence of liver malignancies has increased considerably, and now is the 7th most common cancer, with an incidence of 9.5 per 100,000 across both sexes, worldwide. Several different neoplasms can develop in the liver, with the most common being hepatocellular carcinoma (HCC), followed by cholangiocarcinoma. Whilst these tumors originate in the liver itself, it is more common for cancers originating elsewhere to metastasise to the liver.

Liver tumors can be caused by a number of different factors, including viral infection with HBV/HCV, lifestyle factors (e.g. excessive alcohol consumption), cirrhosis, and various inherited liver diseases.

Surgery remains the standard form of treatment for both primary and secondary tumors, resulting in the best long-term survival rates. The treatment regime will depend on the stage and type of malignancy, with transplantation being a potential option too for some patients. The extent of hepatectomy and resection range will vary depending on numerous factors, such as but not limited to, the location of the tumor within the organ, overall liver function, and spread to nearby vasculature. There are several ongoing and completed clinical trials investigating potential application of adjuvant and neo-adjuvant treatment to improve curability and prolong survival rates. Ongoing research is also further exploring the feasibility and safety of repeat resection in recurrent liver tumors, which remains as one of the most important curative options for recurrence.

This Research Topic welcomes experimental and clinical submissions related to novel insights and developments in the surgical treatment of HCC and liver tumors including, but not limited to advances in hepatectomy, portal vein embolization & ligation, supportive therapy, combination therapy, surgical pathology, neo- and adjuvant treatment options, and technological advances.

Tumors of the liver are one of the most common cancer types worldwide. Over recent decades the rate of incidence of liver malignancies has increased considerably, and now is the 7th most common cancer, with an incidence of 9.5 per 100,000 across both sexes, worldwide. Several different neoplasms can develop in the liver, with the most common being hepatocellular carcinoma (HCC), followed by cholangiocarcinoma. Whilst these tumors originate in the liver itself, it is more common for cancers originating elsewhere to metastasise to the liver.

Liver tumors can be caused by a number of different factors, including viral infection with HBV/HCV, lifestyle factors (e.g. excessive alcohol consumption), cirrhosis, and various inherited liver diseases.

Surgery remains the standard form of treatment for both primary and secondary tumors, resulting in the best long-term survival rates. The treatment regime will depend on the stage and type of malignancy, with transplantation being a potential option too for some patients. The extent of hepatectomy and resection range will vary depending on numerous factors, such as but not limited to, the location of the tumor within the organ, overall liver function, and spread to nearby vasculature. There are several ongoing and completed clinical trials investigating potential application of adjuvant and neo-adjuvant treatment to improve curability and prolong survival rates. Ongoing research is also further exploring the feasibility and safety of repeat resection in recurrent liver tumors, which remains as one of the most important curative options for recurrence.

This Research Topic welcomes experimental and clinical submissions related to novel insights and developments in the surgical treatment of HCC and liver tumors including, but not limited to advances in hepatectomy, portal vein embolization & ligation, supportive therapy, combination therapy, surgical pathology, neo- and adjuvant treatment options, and technological advances.

Download ebook

Share

Editors

Alessandro Vitale

University Hospital of Padua

University Hospital of Padua

Campus Bio-Medico University

Gabriele Spoletini

General Surgery and Liver Transplantation, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Francesco Giovinazzo

Department of Surgery, Saint Camillo Hospital

Impact

133,384 Total views

85,867 Article views

46,547 Article downloads

970 Topic views

Published In

Journal Thumbnail

Frontiers in Oncology

Surgical Oncology

Journal Thumbnail

Frontiers in Surgery

Surgical Oncology

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Suggest a topic